GlassScriptPhysician profile
Thomas L Walden
NPI 1447214028
$1,821.06
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $144 · 2021: $562 · 2022: $480 · 2023: $351 · 2024: $65.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $233.72 | 2019-2022 | |
| Kite Pharma, INC. | $166.30 | 2020-2023 | Yescarta |
| Amgen INC. | $164.33 | 2019-2023 | Kyprolis, Nplate, Xgeva |
| Merck Sharp & Dohme LLC | $126.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $122.21 | 2021-2023 | |
| Exelixis INC. | $121.10 | 2021-2024 | Cabometyx |
| Daiichi Sankyo INC. | $98.30 | 2021-2023 | Enhertu |
| Genzyme Corporation | $64.29 | 2019-2023 | |
| Myovant Sciences INC. | $61.13 | 2021 | |
| Celgene Corporation | $58.61 | 2019-2023 | Reblozyl |
| Lilly USA, LLC | $57.00 | 2021 | |
| Boston Scientific Corporation | $48.37 | 2024 | Spaceoar Vue System - 10ml |
| Seagen INC. | $41.40 | 2022 | |
| Genentech USA, INC. | $39.08 | 2021-2023 | Venclexta |
| Incyte Corporation | $38.32 | 2021-2023 | Jakafi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.04 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $35.27 | 2022 | |
| Varian Medical Systems, INC. | $30.36 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.46 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.02 | 2021 | |
| Eusa Pharma (US) LLC | $23.46 | 2021 | |
| Pfizer INC. | $22.47 | 2023 | |
| Sumitomo Pharma America, INC. | $21.63 | 2023 | Orgovyx |
| Beigene USA, INC. | $19.14 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.36 | 2022 | |
| G1 Therapeutics, INC. | $16.79 | 2022 | |
| Dova Pharmaceuticals | $15.02 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.94 | 2021 | |
| Rigel Pharmaceuticals, INC. | $14.27 | 2022 | |
| Mirati Therapeutics, INC. | $13.93 | 2023 | Krazati |
| Tersera Therapeutics LLC | $11.84 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.84 | 2019 | |
| Advanced Accelerator Applications | $11.50 | 2020 | |
| Sirtex Medical INC | $6.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Walden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.